Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Individualized vs Fixed Dose ATG in Haplo-HSCT
NCT04778618Phase 2Unknown
- Sponsor
- Chinese PLA General Hospital
- Start
- Dec 2020
- Primary completion
- Jul 2022
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of antithymocyte globulin in graft-versus-host disease (GVHD), sponsored by Chinese PLA General Hospital. Status: unknown.
02
Drugs
antithymocyte globulin
03
Conditions
graft-versus-host disease (GVHD)
Beyond the preview
Go deeper on NCT04778618.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04778618.